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Abstract
Objective: To evaluate glycemic variability associated with two different premixed insulin analogue formulations 
when used in a twice-daily regimen.
Patients and Methods: Subjects comprised type 2 diabetic patients aged 20-79 years, treated with twice daily 
premixed insulin or insulin analogue formulations. All subjects were hospitalized for 6 days and randomized to receive 
either Humalog Mix 25 (Mix 25) or Humalog Mix 50 (Mix 50). They were then crossed over to the other arm between 
day 3 and day 4 of the study. Continuous glucose monitoring (CGM) was performed on all subjects to examine the 
differences in glycemic variability.
Results: Eleven type 2 diabetic patients were enrolled. No significant difference was found in 24-hour mean glucose 
values and their SDs, pre-meal glucose values, increases from pre-meal to peak glucose values, or time to peak glucose 
levels between either group. However, the mean glucose values observed during 0-8 hrs were significantly lower with 
Mix 25 compared to Mix 50 (128 vs. 147 mg/dL; p = 0.024).
Conclusions: The twice-daily Mix 25 regimen provided superior overnight glycemic control compared to the Mix 50 
regimen in Japanese patients with type 2 diabetes. However, both twice-daily regimens with either Mix 25 or Mix 50 
provided inadequate post-lunch glycemic control.
Trial Registration: Current Controlled Trials UMIN000001327
Introduction
Results from the Diabetes Control Complications Trial
(DCCT) [1] and the Kumamoto Study [2] demonstrated
that in both type 1 and type 2 diabetes, intensive insulin
therapy combining regular- and intermediate-acting
insulin formulations, provides a significantly greater
improvement in HbA1c values and reduces the onset and
progression of diabetes-associated microangiopathy to a
greater degree, than conventional insulin therapy. These
findings have led to intensive insulin therapy being proac-
tively and increasingly used in diabetic patients.
Following these results, several clinical studies involv-
ing insulin analogue mixtures have been conducted,
which have consistently demonstrated that there is no
significant difference in efficacy between twice-daily regi-
mens with insulin analogue mixtures and intensive insu-
lin therapy. Representative of these, the 4T Study [3]
showed no significant difference in improvement in
HbA1c values between patients treated with intensive
insulin therapy plus an oral anti-diabetic drug (OADD),
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and those treated with a twice-daily mixed insulin ana-
logue regimen plus an OADD. Similar results have been
reported from two independent Japanese studies, the
JOINT and JDDM11 Studies [4,5], conducted in patients
with sulfonylurea secondary failure, which compared the
efficacy between intensive insulin therapy and twice-daily
regimens with insulin analogue mixtures. These results
suggested that twice-daily regimens with insulin analogue
mixtures are as effective as intensive insulin therapy in
improving HbA1c values.
In recent years, insulin analogues combined at different
blend ratios (Humalog Mix 25: 25% lispro, 75% protami-
nated lispro, "Mix 25" hereafter; Humalog Mix 50: 50%
lispro, 50% protaminated lispro, "Mix 50" hereafter) have
become commercially available. However there have
been no reports comparing the effect of these premixed
insulin analogue formulations on glycemic variability
when used in a twice-daily regimen. Therefore, we con-
d u c t e d  a  c r o s s - o v e r  s t u d y  i n  t y p e  2  d i a b e t i c  s u b j e c t s
treated with an identical diet, and used continuous glu-
cose monitoring (CGM) to compare glycemic variability
associated with a twice-daily regimen of either Mix 25 or.
Mix 50.
Patients and Methods
Study subjects comprised type 2 diabetic patients aged
between 20 and less than 80 years old, who were treated
with premixed insulin preparations or premixed insulin
analogue formulations, twice daily. Informed consent was
obtained from all patients prior to starting the study. Sub-
jects were hospitalized during the 6-day study period, and
were randomized to receive either Mix 25 or Mix 50. On
Day 3-4 subjects crossed over to the other study arm.
Insulin injections were given twice daily 0-15 min before
breakfast and before supper. All subjects received the
same insulin dose during hospitalization (Figure 1).
The subjects received test meals consisting of the same
nutrients and equivalent caloric intake on days 3 and 5.
The total caloric intake for subjects was defined by the
attending physicians, as 1,440 kcal (group 1), 1600 kcal
(group 2), or 1,840 kcal (group 3) per day to accommo-
date differences in physique among the subjects. A stan-
dardized test meal was given for breakfast, irrespective of
differences in physique (total calories, 460 kcal; carbohy-
drates, 49.1%; proteins, 15.7%; and lipids, 35.2%) [6] and
commonly available foods were given for lunch and sup-
per.
Midday meals accounted for a total caloric intake of
455 kcal (carbohydrates, 62.2%; proteins, 16.6%; and lip-
ids, 21.2%) in group 1; 571 kcal (carbohydrates, 59.9%;
proteins, 15.7%; and lipids, 24.4%) in group 2; and 684
kcal (carbohydrates, 65.2%; proteins, 14.1%; and lipids,
20.7%) in group 3.
Evening meals accounted for a total caloric intake of
465 kcal (carbohydrates, 56.9%; proteins, 21.6%; and lip-
ids, 21.5%) in group 1; 589 kcal (carbohydrates, 57.7%;
proteins, 20.3%; and lipids, 22.0%) in group 2; and 702
kcal (carbohydrates, 63.2%; proteins, 14.1%; and lipids,
18.7%) in group 3.
The subjects were instructed to refrain from excessive
physical activity, and to maintain a similar level of physi-
cal activity on days 3 and 5 when the test meals were
given.
CGM was performed on all subjects using the CGMS
system GOLD (Medtronic Inc.) [7], which measures
blood glucose every 10 seconds, recording mean values
every 5 minutes. Therefore, 288 measurements were
recorded daily, providing sufficient information to under-
stand diurnal blood glucose variations. The mean glucose
concentrations and their standard deviations (SDs) were
calculated using the CGMS data from 0-24 hrs on day 3
and day 5. Mean 24-hour glucose concentrations and
their SDs, pre-meal glucose concentrations, postprandial
peak glucose concentrations, increases from pre-meal to
peak glucose concentrations, and the time from pre-meal
to peak glucose concentrations were compared using the
Student t-test. Additionally, mean glucose values were
compared between overnight values (from 0-8 hrs) and
those obtained from 8-24 hrs. At the end of the study,
CGM results were disclosed to all subjects, and the insu-
lin regimen was chosen for each patient on the basis of
his/her preference. Statistical analyses were performed
using SPSS 16.0 [8]. The current study was approved by
the Jikei University School of Medicine Ethics Committee
and was registered as Clinical Trial UMIN000001327 [9].
Results
Subjects comprised 11 type 2 diabetic patients (males:
females, 9:2; mean age, 63.9 ± 7.8 years; mean BMI, 24.0 ±
4.0; mean duration of diabetes, 18.0 ± 12.0 years; mean U- Figure 1 Study protocol.
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CPR, 44.3 ± 37.8 μg/day; mean baseline HbA1c value, 8.4
± 2.1%; and mean total daily insulin dose, 24.9 ± 8.9 units)
(Table 1).
No significant difference was found in 24-hour mean
glucose concentrations and their SDs between those
given Mix 25 and those given Mix 50 (176 vs. 187 mg/dL;
50 vs. 49 mg/dL). Similarly, there was no significant dif-
ference between Mix 25 and Mix 50 in pre-meal glucose
concentrations (144 vs. 172 mg/dL in the morning, 151
vs. 153 mg/dL in the daytime, and 161 vs. 177 mg/dL in
the evening); increase from pre-meal to peak glucose
concentrations (93 vs. 85 mg/dL in the morning, 113 vs.
138 mg/dL in the daytime, and 76 vs. 59 mg/dL in the
evening); and time to peak glucose concentrations (98 vs.
93 minutes in the morning, 136 vs. 131 minutes in the
daytime, and 81 vs. 71 minutes in the evening) (Table 2).
However, mean glucose concentrations were signifi-
cantly lower with Mix 25 compared to Mix 50 (128 vs.
147 mg/dL; P = 0.024) in the overnight subgroup analysis
compared to those for the 8-24 hr period. When changes
in the 24-hour mean glucose value were plotted over
time, the overnight glucose level was more favorable with
Mix 25 (Figure 2). However, despite this, asymptomatic
overnight hypoglycemia 60 mg/dL or lower was observed
in 2 patients (18%) with Mix 25, while no overnight hypo-
glycemia was observed with Mix 50.
At the end of the study, when patients were shown their
CGM data and asked to choose their insulin regimen,
more patients (7 patients; 63.6%) chose Mix 25 over Mix
50, given that better glycemic control was noted with Mix
25 overnight while it was not significantly different from
that with Mix 50 during the day.
Discussion
A detailed analysis of differences in glycemic variability
with Mix 25 versus Mix 50 was performed using CGM in
type 2 diabetic patients on insulin therapy.
The mean overnight glucose concentration was signifi-
cantly higher with Mix 50 than Mix 25, with the pre-
breakfast glucose value tending to be higher with Mix 50.
However, the increases in glucose after breakfast were
non-significantly smaller with Mix 50, which had a
greater rapid insulin component than Mix 25. The pre-
lunch glucose values were similar for both groups.
In contrast, the increase in glucose concentration after
lunch was smaller with Mix 25, which had a greater inter-
mediate-acting insulin component. This resulted in the
pre-supper glucose values tending to be slightly higher
with Mix 50.
The increases in the evening glucose concentration
were smaller with Mix 50, similar to that noted after
breakfast, although these increases were not significantly
different from those reported for Mix 25.
Study results clearly demonstrated that the changes in
overnight glucose concentration were significantly lower
with Mix 25, which had a greater intermediate-acting
insulin component than Mix 50. The differences in over-
night changes between Mix 25 and Mix 50 were evident
in each study participant, which led to a non-significantly
greater proportion of the study participants (63.6%)
choosing Mix 25 over Mix 50. However, patients need to
be aware that Mix 25 is associated with a potentially
greater risk for asymptomatic overnight hypoglycemia.
Post-prandial increases in glucose concentration
reflected the differing blend ratios of rapid insulin
between Mix 25 and Mix 50, although this did not result
in significant differences. Interestingly, however, the time
to peak glucose concentration did not clearly reflect these
differing rapid insulin blend ratios, suggesting that these
ratios mainly affected the post-meal increases in glucose
concentration.
Our study results also demonstrated that twice-daily
Mix 25 or Mix 50 regimens provided inadequate glycemic
control after lunch for approximately 4 hours. This sug-
gests that insulin analogue injections 3 times daily are
preferable to 2 times daily to achieve improved glycemic
control and furthermore that Mix 25 injected 3 times
daily or Mix 50 injected before breakfast and lunch fol-
lowed by Mix 25 before supper could represent an ideal
insulin regimen. In this regard, Rosenstock et al com-
pared a 3 times-daily Mix 50 regimen to intensive insulin
therapy (glargine at bedtime plus mealtime lispro) in
patients with inadequate glycemic control [10]. Similar
findings were observed between the two arms with
regard to improvement in HbA1c values or diurnal varia-
tions in blood glucose concentration.
Table 1: Baseline characteristics of the study subjects and 
their total daily insulin doses
Subjects (n) 11
Male (%) 9 (81.9)
HbA1c value (%) at CGM 8.4 ± 2.1
Age (years-old) 63.9 ± 7.8
Body mass index (kg/m2) 24.0 ± 4.0
Duration of diabetes (years) 18.0 ± 12.0
Urinary C-peptide (μg/day) 44.3 ± 37.8
Total insulin dose (U/day) 24.9 ± 8.9
Morning insulin dose (U) 13.7 ± 5.2
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In regard to differences in glycemic variation resulting
from differing blend ratios of mixed insulin analogue
preparations, Hirao et al [11] reported on a cross-over
study comparing biphasic insulin aspart 50 (BIAsp50)
and 30 (BIAsp30) in 10 patients with type 2 diabetes.
Using the euglycemic clamp technique, he demonstrated
that both the serum insulin level and glucose infusion
rate (GIR) were higher with BIAsp50 than with BIAsp30.
To the best of our knowledge, there are only two studies
reported in the literature comparing premixed insulin
analogue formulations and premixed insulin formula-
tions. These were a cross-over study of biphasic insulin
aspart 30 (BIAsp30) versus biphasic human insulin 30
(BHI 30) in 13 type 2 diabetic patients [12] and a random-
ized controlled trial of BIAsp 30 versus BHI 30 in 294
patients with type 1 and type 2 diabetes [13]. Results from
both studies demonstrated that postprandial glucose
increases were suppressed to a significantly greater extent
with BIAsp30 than with BHI 30.
Limitations of the present study include the following:
study subjects had a relatively long mean duration of dis-
ease (18 years) and it is possible that the results may be
different if patients with a shorter duration of disease
were included; that although a cross-over study design
was used, it may not have been adequately powered given
the small sample size (11 patients); and that differences
Table 2: Indices (mean ± SD) for glycemic variation with twice-daily Mix 25 vs. Mix 50 regimens in 11 type 2 diabetic 
patients
Mix 25 regimen Mix 50 regimen P value*
24-hour mean glucose concentration (mg/dL) 176 ± 54 187 ± 41 0.231
SD for 24-hour mean glucose concentration (mg/dL) 50 ± 16 49 ± 11 0.962
Mean glucose concentration 0-8 hrs (mg/dL) 127 ± 52 147 ± 42 0.024
Mean glucose concentration 8-24 hrs (mg/dL) 199 ± 59 206 ± 45 0.514
Lowest glucose concentration (mg/dL) 95 ± 49 105 ± 29 0.464
Peak glucose concentration (mg/dL) 276 ± 62 299 ± 43 0.061
Mean pre-meal glucose concentration (mg/dL)
Pre-breakfast 144 ± 54 172 ± 45 0.496
Pre-lunch 151 ± 72 153 ± 55 0.349
Pre-supper 161 ± 60 177 ± 60 0.997
Increase in postprandial peak glucose concentration 
(mg/dL)
Post-breakfast 93 ± 35 85 ± 28 0.366
Post-lunch 113 ± 43 138 ± 46 0.949
Post-supper 76 ± 28 59 ± 36 0.287
Time to postprandial peak glucose concentration 
(minutes)
Post-breakfast 98 ± 38 93 ± 37 0.667
Post-lunch 136 ± 34 131 ± 21 0.658
Post-supper 81 ± 23 71 ± 21 0.358
*t-test
Figure 2 Changes in mean glucose concentrations over time with 
twice-daily Mix 25 (solid line) vs. Mix 50 (dotted line) regimens in 
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detected may have been found to be significant if more
patients were included.
In conclusion, our study clearly demonstrates that a
twice-daily Mix 25 regimen provides superior overnight
glycemic control compared to twice-daily Mix 50 in Japa-
nese patients with type 2 diabetes. However, the twice-
daily regimen of both Mix 25 and Mix 50 provided inade-
quate post-lunch glycemic control. A randomized com-
parative trial of 3 times-daily regimens with Mix 25
versus Mix 50 in Asian patients needs to be carried out in
the future in order to establish insulin regimens that pro-
vide better glycemic control.
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